Evidence map›Paper›PMID 39330883›Full record

ArticleTropical medicine and infectious disease2024

Concomitant Serological and Molecular Methods for

Ana Lucas Dato, Philp Wikman-Jorgensen, Emilio Borrajo Brunete, María Dolores Hernández Rabadán, Hilarión García-Morante, María Adelino Merino Trigueros, José María Saugar Cruz, Elisa García-Vazquez, Jara Llenas-García

Abstract read
In one paragraph

Article in Tropical medicine and infectious disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ana Lucas DatoInternal Medicine/Infectious Diseases Department, Vega Baja Hospital-Orihuela, 03314 Alicante, Spain.
Philp Wikman-JorgensenFoundation for the Promotion of Health and Biomedical Research of the Valencia Region (FISABIO), 46020 Valencia, Spain.ORCID 0000-0002-6329-0311
Emilio Borrajo BruneteMicrobiology Department, Vega Baja Hospital-Orihuela, 03314 Alicante, Spain.
María Dolores Hernández RabadánInternal Medicine/Infectious Diseases Department, Vega Baja Hospital-Orihuela, 03314 Alicante, Spain.
Hilarión García-MoranteInternal Medicine/Infectious Diseases Department, Vega Baja Hospital-Orihuela, 03314 Alicante, Spain.
María Adelino Merino TriguerosInternal Medicine/Infectious Diseases Department, Vega Baja Hospital-Orihuela, 03314 Alicante, Spain.
José María Saugar CruzLaboratory of Reference and Research in Parasitology, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28222 Majadahonda, Spain.ORCID 0000-0001-8950-5766
Elisa García-VazquezInfectious Diseases Unit, Hospital Virgen de la Arrixaca, 30120 Murcia, Spain.
Jara Llenas-GarcíaInternal Medicine/Infectious Diseases Department, Vega Baja Hospital-Orihuela, 03314 Alicante, Spain.ORCID 0000-0001-9125-7706

Funding

Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana UGP-19031
6 · The paper itself

Abstract

Strongyloidiasis is a widespread parasitic disease that can be life-threatening in immunosuppressed people. In the Mediterranean basin, autochthonous cases coexist with imported ones. We aimed to assess the utility of different screening methods, along with the frequency of strongyloidiasis and its associated risk factors in migrants and the native population. This cross-sectional study took place from 2019 to 2022 in the area of the Vega Baja Hospital in Alicante, Spain. Screening was performed in people who were immunosuppressed, at risk of immunosuppression, with blood asymptomatic eosinophilia, and in asymptomatic people from highly endemic countries. Screening methods were serological techniques (ELISA), stool parasitological tests (fecal concentration methods and agar plate culture), and a stool molecular test (PCR). Of the 168 participants (62.5% males, 53.0% migrants, 36.3% immunosuppressed, median age 57 years), 14 (8.3%) had confirmed strongyloidiasis, where 6 were confirmed by serology, 4 by PCR, and 4 by both methods. Overall, 9% of the migrants and 7.6% of the native-born patients were infected. Elevated IgE and hemoglobin and Latin American origin were associated with strongyloidiasis diagnosis. Screening with serology alone would have missed 28.6% of cases. We conclude that strongyloidiasis prevalence is high in our population, both in native and migrant groups, and stool PCR is a useful tool to increase case detection.

Indexed as

immunosuppressedmigrantsscreeningserologystool PCRStrongyloides

Identifiers

PMID39330883
PMCPMC11435527

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.